Pascal Brière – President, Biogaran, France
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Address: 15 bd Charles de Gaulle 92707 Colombes ,France
Tel: +33 (0)1 55 72 41 00
Biogaran, is an independent French laboratory focused on generic drugs and was born in 1996 at the initiative of the first independent French pharmaceutical group: Servier.
Today the group is second on the French market and produces 55% of its products within the country. The laboratory Biogaran has commissioned the Social Security savings of around € 1 billion since its inception in 1996.
The group distributes a wide variety of pharmaceutical medications through French pharmacies
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France. We…
Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong…
Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy. The product offering remains…
Edouard Bieth, managing director of Tillotts Pharma in France, discusses the opportunities and challenges of opening an affiliate in the country and the uniqueness of Tillotts’ specialization in gastrointestinal drugs.…
The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is…
Arnaud Gobet, president of Innothera, discusses how the company balances its unique and diverse offering of medical devices, hygiene and protection products and pharmaceuticals, Innothera’s burgeoning international footprint and the…
See our Cookie Privacy Policy Here